Abivax relaunches trading of its shares on Euronext Paris

On July 1, 2026, Abivax, a biotechnology company focused on developing treatments for chronic inflammatory diseases, announced the resumption of trading of its ordinary shares on Euronext Paris. This announcement followed the suspension of trading in its shares at 9:00 a.m. CEST the same day, an action taken at the company's request.

The suspension was related to the public offering of American Depositary Shares in the United States. Trading in the shares, each representing one Abivax ordinary share with a par value of €0.01, resumed at 3:30 p.m. CEST. This pause allowed the company to confirm the allocations to investors and announce the final terms of the offering.